These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39197909)

  • 21. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis.
    Takenaka Y; Oya R; Takemoto N; Inohara H
    Head Neck; 2022 May; 44(5):1237-1245. PubMed ID: 35146824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
    Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
    World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy.
    Moon H; Roh JL; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
    Radiother Oncol; 2016 Feb; 118(2):330-4. PubMed ID: 26653356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.
    Ito K; Hashimoto K; Kaira K; Yamaguchi O; Mouri A; Shiono A; Miura Y; Kobayashi K; Imai H; Kuji I; Kagamu H
    Oncol Lett; 2024 Mar; 27(3):110. PubMed ID: 38304175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma.
    Fu M; Li Z; Ma J; Shen F; Zhang X
    Scand J Gastroenterol; 2024 Jun; 59(6):722-729. PubMed ID: 38362884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors.
    Zhang Y; Jin J; Tang M; Li P; Zhou LN; Du YP; Chen MB
    Biomed Res Int; 2022; 2022():6743126. PubMed ID: 35707390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of inflammatory parameters and nutritional index in clinical stage IVB endometrial carcinomas.
    Kiuchi K; Hasegawa K; Ochiai S; Motegi E; Kuno T; Kosaka N; Fukasawa I
    J Obstet Gynaecol; 2019 Feb; 39(2):237-241. PubMed ID: 30370797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy.
    Fang Q; Yu J; Li W; Luo J; Deng Q; Chen B; He Y; Zhang J; Zhou C
    Clin Exp Pharmacol Physiol; 2023 Feb; 50(2):178-190. PubMed ID: 36419356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
    Yang L; Huang Y; Zhou L; Dai Y; Hu G
    Head Neck; 2019 May; 41(5):1525-1535. PubMed ID: 30597654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic biomarkers in metastatic colorectal cancer: delta prognostic nutritional index, delta neutrophil to lymphocyte ratio, and delta platelet to lymphocyte ratio.
    Kocak MZ; Coban S; Araz M; Eryilmaz MK; Artac M
    Support Care Cancer; 2023 May; 31(6):357. PubMed ID: 37246994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significances of systemic inflammatory response markers in patients with synchronous esophageal and head and neck cancers.
    Wang CC; Hsu MH; Lee CT; Chen CJ; Hwang TZ; Wang HP; Lin JT; Wang WL
    Head Neck; 2024 Aug; 46(8):1946-1955. PubMed ID: 38344911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
    Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
    Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
    Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
    Liu J; Gao D; Li J; Hu G; Liu J; Liu D
    Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.